Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Death From Adenocarcinoma of the Lung by Low Dose Aspirin

NCT01707823 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT01707823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01707823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Death From Adenocarcinoma of the Lung by Low Dose Aspirin
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2012
Completion date
August 31, 2018
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the lung, recurrent non-small cell lung cancer, stage ia non-small cell lung cancer, stage ib non-small cell lung cancer, stage iia non-small cell lung cancer, stage iib non-small cell lung cancer, stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer